Geode Capital Management
IMUX icon

Geode Capital Management’s Immunic IMUX Stock Holding History

Geode Capital Management’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.69M Buy
152,577
+34,948
+30% +$313K ﹤0.01% 3187
2025
Q4 		$628K Buy
117,629
+14,252
+14% +$104K ﹤0.01% 3518
2025
Q3 		$912K Buy
103,377
+5,913
+6% +$52.2K ﹤0.01% 3412
2025
Q2 		$680K Sell
97,464
-151
-0.2% -$1.39K ﹤0.01% 3459
2025
Q1 		$1.06M Buy
97,615
+2,386
+3% +$25.8K ﹤0.01% 3288
2024
Q4 		$953K Buy
95,229
+676
+0.7% +$8.52K ﹤0.01% 3401
2024
Q3 		$1.56M Buy
94,553
+927
+1% +$13.2K ﹤0.01% 3199
2024
Q2 		$1.04M Buy
93,626
+4,061
+5% +$50.4K ﹤0.01% 3287
2024
Q1 		$1.18M Buy
89,565
+47,804
+114% +$621K ﹤0.01% 3301
2023
Q4 		$627K Buy
41,761
+2,097
+5% +$25.7K ﹤0.01% 3531
2023
Q3 		$583K Buy
39,664
+4,343
+12% +$83.5K ﹤0.01% 3538
2023
Q2 		$887K Sell
35,321
-1,543
-4% -$25.9K ﹤0.01% 3404
2023
Q1 		$549K Buy
36,864
+9,816
+36% +$182K ﹤0.01% 3609
2022
Q4 		$378K Buy
27,048
+5,371
+25% +$146K ﹤0.01% 3806
2022
Q3 		$684K Buy
21,677
+179
+0.8% +$7.49K ﹤0.01% 3570
2022
Q2 		$745K Sell
21,498
-14,598
-40% -$935K ﹤0.01% 3551
2022
Q1 		$4.08M Buy
36,096
+4,096
+13% +$474K ﹤0.01% 2916
2021
Q4 		$3.06M Buy
32,000
+605
+2% +$54.5K ﹤0.01% 3159
2021
Q3 		$2.78M Buy
31,395
+5,538
+21% +$545K ﹤0.01% 3215
2021
Q2 		$3.17M Buy
25,857
+9,414
+57% +$1.3M ﹤0.01% 3127
2021
Q1 		$2.62M Buy
16,443
+1,210
+8% +$205K ﹤0.01% 3119
2020
Q4 		$2.33M Buy
15,233
+2,313
+18% +$415K ﹤0.01% 3002
2020
Q3 		$2.4M Buy
12,920
+9,462
+274% +$1.55M ﹤0.01% 2781
2020
Q2 		$419K Buy
+3,458
New +$352K ﹤0.01% 3434
2019
Q4 		– Sell
-1,053
Closed -$105K – 4217
2019
Q3 		$105K Sell
1,053
-8
-0.8% -$1.07K ﹤0.01% 3939
2019
Q2 		$121K Sell
1,061
-818
-44% -$107K ﹤0.01% 3915
2019
Q1 		$148K Buy
1,879
+172
+10% +$15.1K ﹤0.01% 3810
2018
Q4 		$127K Buy
1,707
+852
+100% +$99.7K ﹤0.01% 3816
2018
Q3 		$94K Buy
855
+88
+11% +$230K ﹤0.01% 3942
2018
Q2 		$2.1M Buy
767
+285
+59% +$659K ﹤0.01% 2825
2018
Q1 		$1.31M Hold
482
– – ﹤0.01% 2992
2017
Q4 		$1.15M Buy
482
+45
+10% +$99.5K ﹤0.01% 3037
2017
Q3 		$882K Buy
437
+95
+28% +$124K ﹤0.01% 3171
2017
Q2 		$397K Sell
342
-89
-21% -$119K ﹤0.01% 3436
2017
Q1 		$688K Buy
431
+24
+6% +$43.9K ﹤0.01% 3187
2016
Q4 		$708K Buy
407
+12
+3% +$26.3K ﹤0.01% 3148
2016
Q3 		$967K Buy
395
+5
+1% +$12.3K ﹤0.01% 2954
2016
Q2 		$967K Buy
390
+16
+4% +$52.6K ﹤0.01% 2916
2016
Q1 		$1.36K Buy
374
+34
+10% +$118K ﹤0.01% 2719
2015
Q4 		$1.57M Buy
340
+94
+38% +$307K ﹤0.01% 2626
2015
Q3 		$396K Buy
246
+103
+72% +$515K ﹤0.01% 3337
2015
Q2 		$1.21M Buy
143
+21
+17% +$200K ﹤0.01% 2804
2015
Q1 		$1.22M Buy
122
+1
+0.8% +$9.19K ﹤0.01% 2760
2014
Q4 		$1.21M Buy
121
+60
+98% +$462K ﹤0.01% 2728
2014
Q3 		$496K Buy
61
+4
+7% +$37.8K ﹤0.01% 3174
2014
Q2 		$624K Buy
+57
New +$400K ﹤0.01% 3052

Other funds holding IMUX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Geode Capital Management's IMUX Position: Q1 2026 in Review

Geode Capital Management increased its Immunic (IMUX) stake by 30% in Q1 2026, buying an estimated $313K and bringing the position to 152,577 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #3187.

Geode Capital Management first reported a position in IMUX in Q2 2014 and has held it in 46 quarters since. The position peaked at $4.08M in Q1 2022. 75 funds tracked by Wall St. Rank hold IMUX as of Q1 2026.

  • Geode Capital Management held 152,577 shares of Immunic worth $1.69M as of Q1 2026.
  • Geode Capital Management bought 34,948 Immunic shares in Q1 2026, an estimated $313K.
  • Immunic made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3187 holding.
  • Geode Capital Management first reported a position in Immunic in Q2 2014 and has held it in 46 quarters since.
  • Geode Capital Management's Immunic position peaked at $4.08M in Q1 2022.
  • 75 funds tracked by Wall St. Rank held Immunic as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.